Cardiff Oncology, Inc.
NASDAQTotal Valuation
Cardiff Oncology, Inc. carries a market capitalization of 71.00M, placing it among publicly traded companies globally. Its enterprise value stands at 54.99M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 71.00M |
| Enterprise Value | 54.99M |
Share Statistics
Cardiff Oncology, Inc. currently has 68.50M shares outstanding.
| Shares Outstanding | 68.50M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 173.70, and the price-to-book ratio stands at 3.36.
| PE Ratio | N/A |
| PS Ratio | 173.70 |
| PB Ratio | 3.36 |
| P/TBV Ratio | 3.36 |
| P/FCF Ratio | -2.16 |
| P/OCF Ratio | -2.16 |
Enterprise Valuation
| EV / Sales | 108.25 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
Cardiff Oncology, Inc. maintains a current ratio of 3.30, meaning it holds 3.3x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 3.30 |
| Quick Ratio | 3.21 |
| Debt / Equity | 1.72 |
| Debt / EBITDA | -0.01 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | -94.14 |
| Return on Assets (ROA) | -70.84 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Cardiff Oncology, Inc.'s stock has declined approximately -59.97368% over the past 52 weeks. The 50-day moving average sits at 1.09, while the 200-day moving average is 1.53.
| Beta (5Y) | N/A |
| 52-Week Price Change | -59.97368% |
| 50-Day Moving Average | 1.09 |
| 200-Day Moving Average | 1.53 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Cardiff Oncology, Inc. generated 508,000.00 in revenue and converted that into -40.05M in net income, yielding earnings per share of -0.59. EBITDA reached -41.37M, while operating income came in at -42.27M.
| Revenue | 508,000.00 |
| Gross Profit | N/A |
| Operating Income | -42.27M |
| Pretax Income | -40.05M |
| Net Income | -40.05M |
| EBITDA | -41.37M |
| EBIT | -42.27M |
| Earnings Per Share (EPS) | -0.59 |
Balance Sheet
Cardiff Oncology, Inc. holds 34.52M in cash and equivalents against 457,000.00 in total debt, resulting in a net debt position of -9.20M. Total book value stands at 26.53M, with working capital of 24.80M providing operational flexibility.
| Cash & Cash Equivalents | 34.52M |
| Total Debt | 457,000.00 |
| Net Debt | -9.20M |
| Equity (Book Value) | 26.53M |
| Book Value Per Share | 0.39 |
| Working Capital | 24.80M |
Cash Flow
Cardiff Oncology, Inc. produced -40.85M in operating cash flow over the past twelve months.
| Operating Cash Flow | -40.85M |
| Capital Expenditures | N/A |
| Free Cash Flow | -40.85M |
| FCF Per Share | -0.60 |
Margins
Cardiff Oncology, Inc. operates with a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of -8,320.08 and net profit margin of -7,884.06 provide insight into operational efficiency.
| Gross Margin | 100.00 |
| Operating Margin | -8,320.08 |
| Pretax Margin | -7,884.06 |
| Profit Margin | -7,884.06 |
| EBITDA Margin | -8,144.69 |
Dividends & Yields
The company's payout ratio of 0.06 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | 0.06 |
| Shareholder Yield | -3.18 |
| FCF Yield | -46.30 |
Stock Splits
Cardiff Oncology, Inc.'s most recent stock split took place on February 20, 2019 with a 6:1 split ratio.
| Last Split Date | 2/20/2019 |
| Split Ratio | 6:1 |
Scores
Cardiff Oncology, Inc. posts an Altman Z-Score of -14.91, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -14.91 |